Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/42648| Title: | Prolonged hypocalcemia following denosumab therapy in metastatic hormone refractory prostate cancer. | Authors: | Goh S.;Suriadi C.;Gani L.U.;Milat F.;Allan C.A.;Strickland A.H.;Teede H.J. ;Fuller P.J.;Gillespie M.T. | Institution: | (Milat, Goh, Gani, Fuller, Teede, Allan) Department of Endocrinology, Monash Health, Monash Medical Centre, Clayton, Australia (Milat, Gillespie, Fuller) Bone Joint and Cancer Unit, Prince Henry's Institute, Block E, Level 4, Monash Medical Centre, Clayton, Australia (Milat, Fuller, Allan) Department of Medicine, Southern Clinical School, Monash University, Clayton, Australia (Suriadi, Strickland) Monash Cancer Centre, Centre Rd, Bentleigh, Australia (Gillespie, Fuller) Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia (Teede) School of Public Health and Preventive Medicine, Monash University, Clayton, Australia | Issue Date: | 7-Jun-2013 | Copyright year: | 2013 | Publisher: | Elsevier Inc. (360 Park Avenue South, New York NY 10010, United States) | Place of publication: | United States | Publication information: | Bone. 55 (2) (pp 305-308), 2013. Date of Publication: August 2013. | Abstract: | Prostate cancer is a leading cause of cancer death, frequently associated with widespread bone metastases. We report two cases of hypocalcemia following the first dose of denosumab in metastatic hormone refractory prostate cancer, the first case requiring 26. days of intravenous calcium therapy. This is the first report of prolonged hypocalcemia following denosumab in a patient with normal renal function. © 2013 . | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1016/j.bone.2013.04.012 | PubMed URL: | 23685544 [http://www.ncbi.nlm.nih.gov/pubmed/?term=23685544] | ISSN: | 8756-3282 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/42648 | Type: | Article | Subjects: | creatinine blood level diarrhea/si [Side Effect] dose response drug dose reduction drug substitution drug withdrawal febrile neutropenia/si [Side Effect] femur neck fracture/dt [Drug Therapy] human hypocalcemia/dt [Drug Therapy] hypocalcemia/si [Side Effect] *hypocalcemia/dt [Drug Therapy] *hypocalcemia/si [Side Effect] hypophosphatemia/si [Side Effect] lethargy lymph node metastasis/co [Complication] lymph node metastasis/dt [Drug Therapy] patient monitoring QT prolongation/si [Side Effect] side effect/si [Side Effect] single drug dose spinal cord compression/co [Complication] spinal cord compression/dt [Drug Therapy] spinal cord compression/rt [Radiotherapy] spinal cord metastasis/co [Complication] spinal cord metastasis/dt [Drug Therapy] spinal cord metastasis/rt [Radiotherapy] treatment duration urine retention alendronic acid/ae [Adverse Drug Reaction] alendronic acid/cb [Drug Combination] alendronic acid/dt [Drug Therapy] alkaline phosphatase/ec [Endogenous Compound] bicalutamide/cb [Drug Combination] bicalutamide/dt [Drug Therapy] cabazitaxel/dt [Drug Therapy] calcitriol/do [Drug Dose] calcitriol/dt [Drug Therapy] calcitriol/po [Oral Drug Administration] calcium/ec [Endogenous Compound] calcium carbonate/cb [Drug Combination] calcium carbonate/dt [Drug Therapy] calcium carbonate/po [Oral Drug Administration] colecalciferol/cb [Drug Combination] colecalciferol/dt [Drug Therapy] creatinine/ec [Endogenous Compound] *denosumab/ae [Adverse Drug Reaction] *denosumab/do [Drug Dose] *denosumab/dt [Drug Therapy] docetaxel/cb [Drug Combination] docetaxel/dt [Drug Therapy] gluconate calcium/dt [Drug Therapy] gluconate calcium/iv [Intravenous Drug Administration] goserelin/cb [Drug Combination] goserelin/dt [Drug Therapy] phosphorus/dt [Drug Therapy] phosphorus/po [Oral Drug Administration] prostate specific antigen/ec [Endogenous Compound] zoledronic acid/ae [Adverse Drug Reaction] zoledronic acid/cb [Drug Combination] zoledronic acid/dt [Drug Therapy] Chvostek sign Trousseau sign cancer radiotherapy medical history muscle twitch musculoskeletal system parameters palliative therapy aged alkaline phosphatase blood level article bone metastasis/dt [Drug Therapy] *bone metastasis/co [Complication] *bone metastasis/di [Diagnosis] *bone metastasis/dt [Drug Therapy] *bone metastasis/rt [Radiotherapy] bone pain/si [Side Effect] bone scintiscanning calcium blood level cancer combination chemotherapy male case report *castration resistant prostate cancer/dt [Drug Therapy] castration resistant prostate cancer/dt [Drug Therapy] cancer radiotherapy case report *castration resistant prostate cancer / *drug therapy castration resistant prostate cancer / drug therapy creatinine blood level diarrhea / side effect dose response drug dose reduction drug substitution drug withdrawal febrile neutropenia / side effect femur neck fracture / drug therapy human hypocalcemia / drug therapy / side effect *hypocalcemia / *drug therapy / *side effect hypophosphatemia / side effect lethargy lymph node metastasis / complication / drug therapy male medical history muscle twitch musculoskeletal system parameters palliative therapy patient monitoring aged side effect / side effect single drug dose spinal cord compression / complication / drug therapy / radiotherapy spinal cord metastasis / complication / drug therapy / radiotherapy treatment duration urine retention QT prolongation / side effect alkaline phosphatase blood level article bone metastasis / drug therapy *bone metastasis / *complication / *diagnosis / *drug therapy / *radiotherapy bone pain / side effect bone scintiscanning calcium blood level cancer combination chemotherapy |
Type of Clinical Study or Trial: | Case series or case report |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.